ARX788, an antibody-drug conjugate that utilizes UAA-enabled conjugation, has demonstrated potent and selective activities in HER2-low and T-DM1-resistant breast and gastric cancers [31]. The gene discussed is ERBB2; the disease is gastric cancer.